In prostate cancer cells that are resistant to enzalutamide, the enhancer element in CHPT1 SE transcribes lncRNA, namely eRNA, binds to BRD4, and regulates CHPT1 SE activity and CHPT1 expression, mediating androgen-independent drug tolerance [149]. Here, CHPT1 is linked to prostate cancer.